Literature DB >> 6991603

Fc receptors of a human promyelocytic leukemic cell line: evidence for two types of receptors defined by binding of the staphylococcal protein A-IgG1 complex.

G R Crabtree.   

Abstract

The specificity and kinetics of binding of purified monomeric human and murine myeloma immunoglobulins to Fc receptors were studied in a human promyelocytic cell line (HL-60). HL-60 cells contain approximately 20,000 Fc receptors per cell and bind human IgG1, IgG3 and mouse IgG2a with high affinity (dissociation constant of 5 to 10 nM). Kinetic studies of the binding of IgG1 to HL-60 cells demonstrate rapid exchange with ambient immunoglobulin with approximately one-half of the surface-bound IgG1 exchanging every 25 to 30 min at 37 degrees C. Estimation of the equilibrium binding constant from the rates of association and dissociation of IgG1 agrees well with the values obtained from Scatchard analysis of equilibrium binding of radioiodinated IgG1. Approximately one-half of the Fc receptors of HL-60 cells are capable of binding IgG1 complexed to Protein A. This result was independent of the concentration of Protein A (0.5 to 200 microM) or the time of incubation of IgG1 with Protein A. Studies in which Protein A was incubated with HL-60 cells at 37 degrees C then rapidly washed at 0 degrees C indicated that Protein A did not degrade Fc receptors or interact with the Fc receptor sites on HL-60 cells. The complexes formed between Protein A and IgG1 sedimented at 7 to 9S by ultracentrifugation. These results suggest that there are two types of Fc receptors on HL-60 cells, which can be distinguished by their ability to bind the IgG1-Protein A complex.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6991603

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Binding of quinine- and quinidine-dependent drug antibodies to platelets is mediated by the Fab domain of the immunoglobulin G and is not Fc dependent.

Authors:  M E Smith; D M Reid; C E Jones; J V Jordan; C A Kautz; N R Shulman
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

2.  Characterization of the Fc(IgG) receptor on the pluripotential leukaemia cell K-562.

Authors:  A T Ichiki; C J Wust; C B Lozzio
Journal:  Clin Exp Immunol       Date:  1985-01       Impact factor: 4.330

3.  Gamma interferon induces monocytoid differentiation in the HL-60 cell line.

Authors:  E D Ball; P M Guyre; L Shen; J M Glynn; C R Maliszewski; P E Baker; M W Fanger
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

4.  The binding of human immunoglobulin G1 monomer and small, covalently cross-linked polymers of immunoglobulin G1 to human peripheral blood monocytes and polymorphonuclear leukocytes.

Authors:  R J Kurlander; J Batker
Journal:  J Clin Invest       Date:  1982-01       Impact factor: 14.808

5.  Ontogeny of Fc receptors and complement receptor (CR3) during human myeloid differentiation.

Authors:  H B Fleit; S D Wright; C J Durie; J E Valinsky; J C Unkeless
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

6.  Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes.

Authors:  P M Guyre; P M Morganelli; R Miller
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

7.  Human neutrophil Fc gamma receptor distribution and structure.

Authors:  H B Fleit; S D Wright; J C Unkeless
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

8.  Phagocytosis of Streptococcus pyogenes by all-trans retinoic acid-differentiated HL-60 cells: roles of azurophilic granules and NADPH oxidase.

Authors:  Pontus Nordenfelt; Susanne Bauer; Per Lönnbro; Hans Tapper
Journal:  PLoS One       Date:  2009-10-06       Impact factor: 3.240

9.  Immune interferon induces the receptor for monomeric IgG1 on human monocytic and myeloid cells.

Authors:  B Perussia; E T Dayton; R Lazarus; V Fanning; G Trinchieri
Journal:  J Exp Med       Date:  1983-10-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.